» Articles » PMID: 25199801

In Vitro Testing for Diagnosis of Idiosyncratic Adverse Drug Reactions: Implications for Pathophysiology

Overview
Specialty Pharmacology
Date 2014 Sep 10
PMID 25199801
Citations 14
Authors
Affiliations
Soon will be listed here.
Abstract

Idiosyncratic drug reactions (IDRs) represent a major health problem, as they are unpredictable, often severe and can be life threatening. The low incidence of IDRs makes their detection during drug development stages very difficult causing many post-marketing drug withdrawals and black box warnings. The fact that IDRs are always not predictable based on the drug's known pharmacology and have no clear dose-effect relationship with the culprit drug renders diagnosis of IDRs very challenging, if not impossible, without the aid of a reliable diagnostic test. The drug provocation test (DPT) is considered the gold standard for diagnosis of IDRs but it is not always safe to perform on patients. In vitro tests have the advantage of bearing no potential harm to patients. However, available in vitro tests are not commonly used clinically because of lack of validation and their complex and expensive procedures. This review discusses the current role of in vitro diagnostic testing for diagnosis of IDRs and gives a brief account of their technical and mechanistic aspects. Advantages, disadvantages and major challenges that prevent these tests from becoming mainstream diagnostic tools are also discussed here.

Citing Articles

Drug Hypersensitivity Reactions in Patients with Cystic Fibrosis: Potential Value of the Lymphocyte Toxicity Assay to Assess Risk.

Abuzgaia A, Elzagallaai A, Mullowney T, Rieder M Mol Diagn Ther. 2023; 27(3):395-403.

PMID: 36939981 DOI: 10.1007/s40291-023-00644-3.


Bridging the gap between bench and clinic: the importance of understanding the mechanism of iodinated contrast media hypersensitivity.

Sullivan C, Paul N, Rieder M Br J Radiol. 2022; 96(1141):20220494.

PMID: 36395475 PMC: 10997019. DOI: 10.1259/bjr.20220494.


The role of testing in pharmacovigilance for ß-lactam-induced serum sickness-like reaction: A pilot study.

Elzagallaai A, Abuzgaia A, Del Pozzo-Magana B, Loubani E, Rieder M Front Pharmacol. 2022; 13:945545.

PMID: 36110527 PMC: 9468642. DOI: 10.3389/fphar.2022.945545.


Carba Analogues of Flupirtine and Retigabine with Improved Oxidation Resistance and Reduced Risk of Quinoid Metabolite Formation.

Wurm K, Bartz F, Schulig L, Bodtke A, Bednarski P, Link A ChemMedChem. 2022; 17(16):e202200262.

PMID: 35687532 PMC: 9541272. DOI: 10.1002/cmdc.202200262.


Paediatric serum sickness-like reaction: A 10-year retrospective cohort study.

Del Pozzo-Magana B, Abuzgaia A, Murray B, Rieder M, Lazo-Langner A Paediatr Child Health. 2021; 26(7):428-435.

PMID: 34777661 PMC: 8581535. DOI: 10.1093/pch/pxab003.


References
1.
Bates D, Cullen D, Laird N, Petersen L, Small S, Servi D . Incidence of adverse drug events and potential adverse drug events. Implications for prevention. ADE Prevention Study Group. JAMA. 1995; 274(1):29-34. View

2.
Earnshaw C, Pecaric-Petkovic T, Park B, Naisbitt D . T cell responses to drugs and drug metabolites. Exp Suppl. 2013; 104:137-63. DOI: 10.1007/978-3-0348-0726-5_10. View

3.
Pichler W, Tilch J . The lymphocyte transformation test in the diagnosis of drug hypersensitivity. Allergy. 2004; 59(8):809-20. DOI: 10.1111/j.1398-9995.2004.00547.x. View

4.
Elzagallaai A, Koren G, Bend J, Rieder M . In vitro testing for hypersensitivity-mediated adverse drug reactions: challenges and future directions. Clin Pharmacol Ther. 2011; 90(3):455-60. DOI: 10.1038/clpt.2011.155. View

5.
Uetrecht J, Naisbitt D . Idiosyncratic adverse drug reactions: current concepts. Pharmacol Rev. 2013; 65(2):779-808. PMC: 3639727. DOI: 10.1124/pr.113.007450. View